Seeking AlphaCodex · 实盘不做把握 8/10
北京时间·🕒 发布 19:34:07时区推断·⟳ 抓取 19:37:40·⚡ 决策 07-24 19:38:53 +1m13s·95.0 天前
HCA Healthcare二季度业绩快讯为已处理同题催化的重复转述
本条Seeking Alpha快讯与近72小时已处理的HCA Healthcare二季度业绩及全年指引同题，不能重复出卡。
📄 原文Seeking Alpha↗ 原文
HCA Healthcare beats top-line and bottom-line estimates; updates FY2026 outlook
HCA Healthcare press release (HCA): Q2 Non-GAAP EPS of $7.59 beats by $0.09. Revenue of $20.23B (+8.7% Y/Y) beats by $4…
不做 HCA Healthcare（HCA.US）
同一具体催化已在内部处理库命中：19:35已有“HCA Healthcare发布二季度正式业绩，但核心数字和全年指引已在7月14日预披露”的不做结论，本条Seeking Alpha仅为重复转述，不重复出卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-24 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本条Seeking Alpha快讯与近72小时已处理的HCA Healthcare二季度业绩及全年指引同题，不能重复出卡。
- 业绩本身为收入和EPS小幅超预期、但全年净利/EPS/EBITDA指引下调的混合财报事件。
主要风险
- 若后续公司电话会披露新的 payer mix 或 Medicaid 补助口径变化，应由新信号重新研判。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,674 字
HCA Healthcare press release (HCA): Q2 Non-GAAP EPS of $7.59 beats by $0.09.
Revenue of $20.23B (+8.7% Y/Y) beats by $490M.
Adjusted EBITDA increased 4.6 percent to $4.027 billion
Cash flows from operating activities totaled $2.335 billion, compared to $4.210 billion in the second quarter of 2025
Same facility admissions increased 2.5 percent and same facility equivalent admissions increased 2.7 percent.
2026 Updated Guidance and Key Assumptions
Based on results through the first half of the year, the Company has revised its 2026 guidance as follows:
Previous 2026 Guidance Ranges, as of January 27, 2026
Revised 2026 Guidance Ranges, as of July 14, 2026
Revenues
$76.500 to $80.000 billion
$77.000 to $79.500 billion vs. consensus of $78.49B
Net Income Attributable to HCA Healthcare, Inc.
$6.495 to $7.035 billion
$6.300 to $6.700 billion
Adjusted EBITDA
$15.550 to $16.450 billion
$15.400 to $16.100 billion
EPS (diluted)
$29.10 to $31.50 per diluted share
$28.70 to $30.50 per diluted share vs. consensus of $29.92
The Company revised its 2026 key assumptions related to the unfavorable impact on income before income taxes from payer mix shifts due to the health insurance exchanges, as well as the incremental net benefit from Medicaid Supplemental Payment Programs, as follows:
Previous 2026 Estimates, as of April 24, 2026
Revised 2026 Estimates, as of July 14, 2026
Health Insurance Exchanges
($600) to ($900) million
($1.000) to ($1.200) billion
Medicaid Supplemental Payment Programs
($50) to ($250) million
$300 to $500 million
The Company's 2026 estimate for capital expenditures of $5.0 billion to $5.5 billion, excluding acquisitions, remains unchanged.
Revenue of $20.23B (+8.7% Y/Y) beats by $490M.
Adjusted EBITDA increased 4.6 percent to $4.027 billion
Cash flows from operating activities totaled $2.335 billion, compared to $4.210 billion in the second quarter of 2025
Same facility admissions increased 2.5 percent and same facility equivalent admissions increased 2.7 percent.
2026 Updated Guidance and Key Assumptions
Based on results through the first half of the year, the Company has revised its 2026 guidance as follows:
Previous 2026 Guidance Ranges, as of January 27, 2026
Revised 2026 Guidance Ranges, as of July 14, 2026
Revenues
$76.500 to $80.000 billion
$77.000 to $79.500 billion vs. consensus of $78.49B
Net Income Attributable to HCA Healthcare, Inc.
$6.495 to $7.035 billion
$6.300 to $6.700 billion
Adjusted EBITDA
$15.550 to $16.450 billion
$15.400 to $16.100 billion
EPS (diluted)
$29.10 to $31.50 per diluted share
$28.70 to $30.50 per diluted share vs. consensus of $29.92
The Company revised its 2026 key assumptions related to the unfavorable impact on income before income taxes from payer mix shifts due to the health insurance exchanges, as well as the incremental net benefit from Medicaid Supplemental Payment Programs, as follows:
Previous 2026 Estimates, as of April 24, 2026
Revised 2026 Estimates, as of July 14, 2026
Health Insurance Exchanges
($600) to ($900) million
($1.000) to ($1.200) billion
Medicaid Supplemental Payment Programs
($50) to ($250) million
$300 to $500 million
The Company's 2026 estimate for capital expenditures of $5.0 billion to $5.5 billion, excluding acquisitions, remains unchanged.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。